Preclinical development of SIG-007 for treatment of Fabry disease

被引：0
|
作者：
Fluharty, Brian [1 ]
Makino, Elina [1 ]
Donovan, Marissa [1 ]
Tietz, Drew [1 ]
Pearson, Erika [1 ]
Jansen, Lauren [1 ]
Barney, Lauren [1 ]
Sewell, Jared [1 ]
Huang, Janet [1 ]
Corzo, Deya [1 ]
Moller, David [1 ]
Peritt, David [1 ]
Vivaldi, Rogerio [1 ]
机构：
[1] Sigilon Therapeut, Cambridge, MA USA
来源：
MOLECULAR GENETICS AND METABOLISM | 2020年 / 129卷 / 02期
关键词：
D O I：
10.1016/j.ymgme.2019.11.130
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
121
引用
收藏
页码：S57 / S57
页数：1
相关论文
共 50 条
  • [1] SIG-007: Novel encapsulated non-viral cell-based therapy for Fabry disease
    Fluharty, Brian
    Tietz, Drew
    Jansen, Lauren
    Huang, Janet
    Li, Jie
    Schladenhauffen, Jacob
    McAuliffe, Michele
    Kelley, Elizabeth
    Glyptis, Tina
    Barrett, Verna Zhao Kathleen
    Drapeau, Susan
    Smith, Devyn
    Makino, Elina
    MOLECULAR GENETICS AND METABOLISM, 2021, 132 (02) : S39 - S39
  • [2] Development of a Biosimilar of Agalsidase Beta for the Treatment of Fabry Disease: Preclinical Evaluation
    van Kuilenburg, Andre B. P.
    Hollak, Carla E. M.
    Travella, Ana
    Jacobs, Melisa
    Gentilini, Lucas D.
    Leen, Rene
    van der Vlugt, Karen M. M. Ghauharali
    Stet, Femke S. Beers
    Goorden, Susan M. I.
    van der Veen, Sanne
    Criscuolo, Marcelo
    Papouchado, Mariana
    DRUGS IN R&D, 2023, 23 (02) : 141 - 153
  • [3] Development of a Biosimilar of Agalsidase Beta for the Treatment of Fabry Disease: Preclinical Evaluation
    André B. P. van Kuilenburg
    Carla E. M. Hollak
    Ana Travella
    Melisa Jacobs
    Lucas D. Gentilini
    René Leen
    Karen M. M. Ghauharali-van der Vlugt
    Femke S. Beers Stet
    Susan M. I. Goorden
    Sanne van der Veen
    Marcelo Criscuolo
    Mariana Papouchado
    Drugs in R&D, 2023, 23 : 141 - 153
  • [4] Preclinical development of SIG-005 for treatment of MPS I
    Donovan, Marissa
    Makino, Elina
    Fluharty, Brian
    Tietz, Drew
    Pearson, Erika
    Jansen, Lauren
    Barney, Lauren
    Sewell, Jared
    Huang, Janet
    Corzo, Deya
    Moller, David
    Peritt, David
    Vivaldi, Rogerio
    MOLECULAR GENETICS AND METABOLISM, 2020, 129 (02) : S50 - S50
  • [5] Fabry disease pain: patient and preclinical parallels
    Burand, Anthony J., Jr.
    Stucky, Cheryl L.
    PAIN, 2021, 162 (05) : 1305 - 1321
  • [6] Treatment in Fabry disease
    Lopez Rodriguez, M.
    REVISTA CLINICA ESPANOLA, 2018, 218 (09): : 489 - 495
  • [7] Clinical development of agalsidase-beta for the treatment of Fabry disease
    Germain, DP
    M S-MEDECINE SCIENCES, 2005, 21 : 57 - 61
  • [8] The preclinical discovery and development of opicapone for the treatment of Parkinson's disease
    Ettcheto, Miren
    Busquets, Oriol
    Sanchez-Lopez, Elena
    Cano, Amanda
    Manzine, Patricia R.
    Verdaguer, Ester
    Olloquequi, Jordi
    Auladell, Carme
    Folch, Jaume
    Camins, Antoni
    EXPERT OPINION ON DRUG DISCOVERY, 2020, 15 (09) : 993 - 1003
  • [9] Options in the treatment of Fabry disease
    Möhrenschlager, M
    Ring, J
    Abeck, D
    PEDIATRIC DERMATOLOGY, 2003, 20 (04) : 373 - 374
  • [10] Migalastat for the treatment of Fabry disease
    Sunder-Plassmann, Gere
    Schiffmann, Raphael
    Nicholls, Kathleen
    EXPERT OPINION ON ORPHAN DRUGS, 2018, 6 (05): : 301 - 309
12345